News Quantified

AFMD – affimed n.v. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)

Affimed (NASDAQ: AFMD) had its price target lowered by analysts at Wells Fargo & Company from $20.00 to $15.00. They now have an "overweight" rating on the stock.

Affimed (NASDAQ: AFMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.

Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer

-2.7%

BEAT

-4.3%

MISS

2.2%

BEAT

Cantor Fitzgerald

Cantor Fitzgerald

Form 6-K Affimed N.V. For: Dec 17

Form 6-K Affimed N.V. For: Nov 14

Form EFFECT Affimed N.V.

Form 424B5 Affimed N.V.

Form F-3 Affimed N.V.

Top News Gainers

3/17 Affimed Announces Appointment of Arndt Schottelius, M.D. Ph.D. as Chief Scientific Officer 27.5%

10/15 Affimed Reports Progress on Key Clinical Development Programs 10.6%

4/14 Affimed NV (NASDAQ: AFMD) had its "outperform" rating re-affirmed by analysts at SVB Leerink LLC. 8.1%

12/17 Affimed Announces Addition to NASDAQ Biotechnology Index 6.9%

8/8 Affimed NV (NASDAQ: AFMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.1%

6/12 Affimed to Present Data on AFM13 at the 15th International Conference on Malignant Lymphoma in Lugano, Switzerland 4.7%

11/13 Affimed Announces Closing of Public Offering of Common Shares and Exercise of Underwriters’ Option to Purchase Additional Shares 3.9%

11/22 Affimed NV (NASDAQ: AFMD) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong sell" rating. 3.3%

4/1 Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell Lymphoma 3.1%

8/29 Affimed NV (NASDAQ: AFMD) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 2.9%

Top News Decliners

11/12 Form 424B5 Affimed N.V. -13.3%

11/7 Form 6-K Affimed N.V. For: Nov 07 -11.1%

5/22 Q1/2019 3/31/2019 EPS 0.030 ZacksConsensus -0.160 ActVsEst 0.190 - Beat -10.4%

4/28 Form 6-K Affimed N.V. For: Apr 28 -7.1%

8/9 Affimed N.V. (AFMD) Q2 2019 Earnings Call Transcript [The Motley Fool] -6.5%

3/24 Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies -5.8%

8/7 Q2/2019 6/30/2019 EPS -0.170 ZacksConsensus -0.160 ActVsEst (0.010) - Miss -4.9%

11/19 Q3/2019 9/30/2019 EPS -0.170 ZacksConsensus -0.140 ActVsEst (0.030) - Miss -4.5%

4/2 Affimed Provides COVID-19-Related Business Update and Announces Full Year 2019 Financial Results Conference Call on April 28, 2020 -3.5%

6/4 Affimed Announces Annual General Meeting of Shareholders -3.3%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day